Vasilios Karageorgiou1, Gerasimos P Milas2, Ioannis Michopoulos3. 1. Faculty of Medicine, National and Kapodistrian University of Athens, Mikras Asias 75, Goudi, Athens 11527, Greece. Electronic address: vaskarageorg@hotmail.com. 2. Faculty of Medicine, National and Kapodistrian University of Athens, Mikras Asias 75, Goudi, Athens 11527, Greece. 3. 2(nd) Psychiatric Department of the University of Athens, Attikon Hospital, Rimini 1, Chaidari, Athens 12243, Greece.
Abstract
BACKGROUND: The immune system appears to be dysregulated in schizophrenia (SZ). The potential prognostic or diagnostic value of neutrophil-to-lymphocyte ratio (NLR), an inexpensive proxy marker for a wide spectrum of conditions, has not been established in SZ. We seek to investigate a) whether NLR is increased in SZ patients, b) if this difference in more prominent in relapsed SZ or first-episode psychosis. METHODS: A structured algorithm was applied in MEDLINE (1946-2018), PsychInfo, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) (1999-2018), PSYNDEX (1984-2017) and Clinicaltrials.gov (2008-2018) databases. RESULTS: Through the database search, 1023 articles were screened. Ten studies (804 SZ patients, 671 controls) were included in the meta-analysis. In SZ patients, the NLR was increased by 0.65 (95% CI: 0.54, 0.86, p < 10-5). This difference was significant in both acute relapse and first-episode psychosis subgroups. Studies of moderate and high quality also showed a significant NLR increase in SZ patients (I2 = 0%). Meta-regression analysis showed that the polymorphonuclear count and antipsychotic use may confound the result. In leave-one-out meta-analysis, no study altered the significance of the result when omitted. CONCLUSIONS: NLR in SZ patients is increased, both in chronic disease and in first-episode psychosis. Baseline characteristics, such as polymorphonuclear count and antipsychotic use, may affect its accuracy. The application of this marker in clinical practice requires the description of its normal values in the general population, its potential change after antipsychotic administration and its correlation with disease activity. A large-scale, prospective study design would resolve these issues.
BACKGROUND: The immune system appears to be dysregulated in schizophrenia (SZ). The potential prognostic or diagnostic value of neutrophil-to-lymphocyte ratio (NLR), an inexpensive proxy marker for a wide spectrum of conditions, has not been established in SZ. We seek to investigate a) whether NLR is increased in SZ patients, b) if this difference in more prominent in relapsed SZ or first-episode psychosis. METHODS: A structured algorithm was applied in MEDLINE (1946-2018), PsychInfo, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) (1999-2018), PSYNDEX (1984-2017) and Clinicaltrials.gov (2008-2018) databases. RESULTS: Through the database search, 1023 articles were screened. Ten studies (804 SZ patients, 671 controls) were included in the meta-analysis. In SZ patients, the NLR was increased by 0.65 (95% CI: 0.54, 0.86, p < 10-5). This difference was significant in both acute relapse and first-episode psychosis subgroups. Studies of moderate and high quality also showed a significant NLR increase in SZ patients (I2 = 0%). Meta-regression analysis showed that the polymorphonuclear count and antipsychotic use may confound the result. In leave-one-out meta-analysis, no study altered the significance of the result when omitted. CONCLUSIONS: NLR in SZ patients is increased, both in chronic disease and in first-episode psychosis. Baseline characteristics, such as polymorphonuclear count and antipsychotic use, may affect its accuracy. The application of this marker in clinical practice requires the description of its normal values in the general population, its potential change after antipsychotic administration and its correlation with disease activity. A large-scale, prospective study design would resolve these issues.
Authors: M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker Journal: Mol Psychiatry Date: 2022-04-28 Impact factor: 15.992
Authors: Eilis Hannon; Emma L Dempster; Georgina Mansell; Joe Burrage; Nick Bass; Marc M Bohlken; Aiden Corvin; Charles J Curtis; David Dempster; Marta Di Forti; Timothy G Dinan; Gary Donohoe; Fiona Gaughran; Michael Gill; Amy Gillespie; Cerisse Gunasinghe; Hilleke E Hulshoff; Christina M Hultman; Viktoria Johansson; René S Kahn; Jaakko Kaprio; Gunter Kenis; Kaarina Kowalec; James MacCabe; Colm McDonald; Andrew McQuillin; Derek W Morris; Kieran C Murphy; Colette J Mustard; Igor Nenadic; Michael C O'Donovan; Diego Quattrone; Alexander L Richards; Bart Pf Rutten; David St Clair; Sebastian Therman; Timothea Toulopoulou; Jim Van Os; John L Waddington; Patrick Sullivan; Evangelos Vassos; Gerome Breen; David Andrew Collier; Robin M Murray; Leonard S Schalkwyk; Jonathan Mill Journal: Elife Date: 2021-02-26 Impact factor: 8.140
Authors: Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg Journal: Behav Brain Res Date: 2021-01-14 Impact factor: 3.332
Authors: Márton Áron Kovács; Tamás Tényi; Réka Kugyelka; Lilla Prenek; Lídia Hau; Éva Erzsébet Magyar; Róbert Herold; Péter Balogh; Diána Simon Journal: Front Psychiatry Date: 2020-01-23 Impact factor: 4.157
Authors: Johann Steiner; Thomas Frodl; Kolja Schiltz; Henrik Dobrowolny; Roland Jacobs; Brisa S Fernandes; Paul C Guest; Gabriela Meyer-Lotz; Katrin Borucki; Sabine Bahn; Bernhard Bogerts; Peter Falkai; Hans-Gert Bernstein Journal: Schizophr Bull Date: 2020-02-26 Impact factor: 9.306